A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522713-29-00

Enrollment

Registered

2026-03-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Brief summary

rPFS, measured as the time from randomization to the time of radiographic disease progression per PCWG3 and RECIST v1.1 as assessed by BICR on CT/MRI or bone scan, or death from any cause, whichever occurs first.

Interventions

DRUGPrednison acis 5 mg

DRUGTabletten

DRUGDocetaxel AqVida 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

DRUGDOCETAXEL

DRUGJNJ-78278343

DRUGPREDNISONE

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
rPFS, measured as the time from randomization to the time of radiographic disease progression per PCWG3 and RECIST v1.1 as assessed by BICR on CT/MRI or bone scan, or death from any cause, whichever occurs first.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 11, 2026